000864916 001__ 864916
000864916 005__ 20210130002750.0
000864916 037__ $$aFZJ-2019-04519
000864916 1001_ $$0P:(DE-Juel1)145110$$aLohmann, Philipp$$b0$$eCorresponding author$$ufzj
000864916 1112_ $$aGermany$$cBremen$$d2019-04-03 - 2019-04-06$$wBremen
000864916 245__ $$aFET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma.
000864916 260__ $$c2019
000864916 3367_ $$0PUB:(DE-HGF)1$$2PUB:(DE-HGF)$$aAbstract$$babstract$$mabstract$$s1567756496_28189
000864916 3367_ $$033$$2EndNote$$aConference Paper
000864916 3367_ $$2BibTeX$$aINPROCEEDINGS
000864916 3367_ $$2DRIVER$$aconferenceObject
000864916 3367_ $$2DataCite$$aOutput Types/Conference Abstract
000864916 3367_ $$2ORCID$$aOTHER
000864916 520__ $$aV54FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastomaP. Lohmann1, P. Stavrinou2, K. Lipke1, E. K. Bauer3, G. Ceccon3, J. Werner3, B. Neumaier1, G. R. Fink3, N. J. Shah1, K. Langen1, N. Galldiks31Forschungszentrum Jülich, Institute of Neuroscience and Medicine, Jülich; 2University of Cologne, Dept. of Neurosurgery, Cologne; 3University of Cologne, Dept. of Neurology, CologneZiel/Aim:Contrast enhancement (CE) in MRI is usually the target for resection or radiotherapy target volume definition in glioblastomas. However, the solid tumour mass may extend beyond areas of CE. Amino acid PET can detect such tumour parts that show no CE. We systematically investigated tumour volumes delineated by amino acid PET and MRI in newly diagnosed, untreated glioblastoma patients.Methodik/Methods:Preoperatively, 50 patients with neuropathologically confirmed glioblastoma underwent O-(2-[F-18]-fluoroethyl)-L-tyrosine (FET) PET, fluid-attenuated inversion recovery (FLAIR) and contrast-enhanced MRI. Areas of CE were manually segmented. FET PET tumour volumes were segmented using a tumour-to-brain ratio of 1.6. The percentage of overlapping volumes (OV), Dice and Jaccard spatial similarity coefficients (DSC; JSC) were calculated. FLAIR images were evaluated visually.Ergebnisse/Results:In 86% of patients (n = 43), the FET tumour volume was significantly larger than the volume of CE (21.5 ± 14.3 mL vs. 9.4 ± 11.3 mL; P < 0.001). Forty patients (80%) showed both an increased uptake of FET and CE. In these 40 patients, the spatial similarity between FET and CE was low (mean DSC, 0.39 ± 0.21; mean JSC, 0.26 ± 0.16). Ten patients (20%) showed no CE, and one of these patients showed no FET uptake. In 10% of patients (n = 5), increased FET uptake was present outside of areas of FLAIR hyperintensity.Schlussfolgerungen/Conclusions:Our data show that the metabolically active tumour volume delineated by FET PET is significantly larger than tumour volume delineated by CE. Furthermore, the data strongly suggest that the information derived from both imaging modalities should be integrated into the management of newly diagnosed glioblastoma patients.
000864916 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000864916 7001_ $$0P:(DE-HGF)0$$aStavrinou, P.$$b1
000864916 7001_ $$0P:(DE-HGF)0$$aLipke, K.$$b2
000864916 7001_ $$0P:(DE-HGF)0$$aBauer, E. K.$$b3
000864916 7001_ $$0P:(DE-HGF)0$$aCeccon, G.$$b4
000864916 7001_ $$0P:(DE-HGF)0$$aWerner, J. M.$$b5
000864916 7001_ $$0P:(DE-Juel1)166419$$aNeumaier, B.$$b6$$ufzj
000864916 7001_ $$0P:(DE-Juel1)131720$$aFink, G. R.$$b7$$ufzj
000864916 7001_ $$0P:(DE-Juel1)131794$$aShah, N. J.$$b8$$ufzj
000864916 7001_ $$0P:(DE-Juel1)131777$$aLangen, K. J.$$b9$$ufzj
000864916 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, N.$$b10$$ufzj
000864916 8564_ $$uhttps://www.nuklearmedizin.de/jahrestagungen/abstr_online2019/abstract_detail.php?navId=227&aId=11
000864916 909CO $$ooai:juser.fz-juelich.de:864916$$pVDB
000864916 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145110$$aForschungszentrum Jülich$$b0$$kFZJ
000864916 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166419$$aForschungszentrum Jülich$$b6$$kFZJ
000864916 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b7$$kFZJ
000864916 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131794$$aForschungszentrum Jülich$$b8$$kFZJ
000864916 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b9$$kFZJ
000864916 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b10$$kFZJ
000864916 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000864916 9141_ $$y2019
000864916 920__ $$lyes
000864916 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000864916 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000864916 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x2
000864916 980__ $$aabstract
000864916 980__ $$aVDB
000864916 980__ $$aI:(DE-Juel1)INM-3-20090406
000864916 980__ $$aI:(DE-Juel1)INM-4-20090406
000864916 980__ $$aI:(DE-Juel1)INM-5-20090406
000864916 980__ $$aUNRESTRICTED